{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:46:16Z","timestamp":1791200776549,"version":"4.2.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,7]],"date-time":"2012-12-07T00:00:00Z","timestamp":1354838400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuromol Med"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s12017-012-8208-8","type":"journal-article","created":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T21:13:24Z","timestamp":1354742004000},"page":"169-179","source":"Crossref","is-referenced-by-count":18,"title":["A\u03b21-15\/16 as a Potential Diagnostic Marker in Neurodegenerative Diseases"],"prefix":"10.1007","volume":"15","author":[{"given":"Magdalena","family":"Nutu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Portelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Andreasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Parent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lipari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,7]]},"reference":[{"issue":"5","key":"8208_CR1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/mds.10714","volume":"19","author":"WF Abdo","year":"2004","unstructured":"Abdo, W. F., De Jong, D., Hendriks, J. C., Horstink, M. W., Kremer, B. P., Bloem, B. R., et al. (2004). Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson\u2019s disease. Movement Disorders, 19(5), 571\u2013579.","journal-title":"Movement Disorders"},{"issue":"1","key":"8208_CR2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mds.23341","volume":"26","author":"MB Aerts","year":"2011","unstructured":"Aerts, M. B., Esselink, R. A., Bloem, B. R., & Verbeek, M. M. (2011). Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome. Movement Disorders, 26(1), 169\u2013173.","journal-title":"Movement Disorders"},{"issue":"5","key":"8208_CR3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/archneur.1997.00550170111022","volume":"54","author":"O Almkvist","year":"1997","unstructured":"Almkvist, O., Basun, H., Wagner, S. L., Rowe, B. A., Wahlund, L. O., & Lannfelt, L. (1997). Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation. Archives of Neurology, 54(5), 641\u2013644.","journal-title":"Archives of Neurology"},{"key":"8208_CR4","unstructured":"American Psychiatric Association., A. P. A. (1987). Diagnostic and statistical manual of mental disorders, Third Edition, Revised. Washington D.C."},{"issue":"4","key":"8208_CR5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/jnnp.71.4.557","volume":"71","author":"N Andreasen","year":"2001","unstructured":"Andreasen, N., Gottfries, J., Vanmechelen, E., Vanderstichele, H., Davidson, P., Blennow, K., et al. (2001). Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer\u2019s disease. Journal of Neurology, Neurosurgery and Psychiatry, 71(4), 557\u2013558.","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"1","key":"8208_CR6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2217\/17520363.1.1.59","volume":"1","author":"U Andreasson","year":"2007","unstructured":"Andreasson, U., Portelius, E., Andersson, M. E., Blennow, K., & Zetterberg, H. (2007). Aspects of beta-amyloid as a biomarker for Alzheimer\u2019s disease. Biomarkers in Medicine, 1(1), 59\u201378.","journal-title":"Biomarkers in Medicine"},{"issue":"9770","key":"8208_CR7","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","volume":"377","author":"C Ballard","year":"2011","unstructured":"Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011). Alzheimer\u2019s disease. Lancet, 377(9770), 1019\u20131031.","journal-title":"Lancet"},{"issue":"1","key":"8208_CR8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.21623","volume":"66","author":"RJ Bateman","year":"2009","unstructured":"Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., et al. (2009). A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Annals of Neurology, 66(1), 48\u201354.","journal-title":"Annals of Neurology"},{"issue":"3","key":"8208_CR9","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3233\/JAD-2011-110566","volume":"27","author":"M Bjerke","year":"2011","unstructured":"Bjerke, M., Zetterberg, H., Edman, A., Blennow, K., Wallin, A., & Andreasson, U. (2011). Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer\u2019s disease. Journal of Alzheimers Disease, 27(3), 665\u2013676.","journal-title":"Journal of Alzheimers Disease"},{"issue":"2","key":"8208_CR10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1602\/neurorx.1.2.213","volume":"1","author":"K Blennow","year":"2004","unstructured":"Blennow, K. (2004). Cerebrospinal fluid protein biomarkers for Alzheimer\u2019s disease. NeuroRx, 1(2), 213\u2013225.","journal-title":"NeuroRx"},{"issue":"10","key":"8208_CR11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","volume":"2","author":"K Blennow","year":"2003","unstructured":"Blennow, K., & Hampel, H. (2003). CSF markers for incipient Alzheimer\u2019s disease. Lancet Neurology, 2(10), 605\u2013613.","journal-title":"Lancet Neurology"},{"issue":"3","key":"8208_CR12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews. Neurology, 6(3), 131\u2013144.","journal-title":"Nature Reviews. Neurology"},{"key":"8208_CR13","first-page":"1","volume":"48","author":"H Braak","year":"1996","unstructured":"Braak, H., Braak, E., Yilmazer, D., de Vos, R. A., Jansen, E. N., & Bohl, J. (1996). New aspects of pathology in Parkinson\u2019s disease with concomitant incipient Alzheimer\u2019s disease. Journal of Neural Transmission. Supplementum, 48, 1\u20136.","journal-title":"Journal of Neural Transmission. Supplementum"},{"issue":"5","key":"8208_CR14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/jms.2987","volume":"47","author":"G Brinkmalm","year":"2012","unstructured":"Brinkmalm, G., Portelius, E., Ohrfelt, A., Mattsson, N., Persson, R., Gustavsson, M. K., et al. (2012). An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid beta and amyloid precursor protein in human and cat cerebrospinal fluid. Journal of Mass Spectrometry, 47(5), 591\u2013603.","journal-title":"Journal of Mass Spectrometry"},{"issue":"19","key":"8208_CR15","doi-asserted-by":"crossref","first-page":"6743","DOI":"10.1523\/JNEUROSCI.1381-10.2010","volume":"30","author":"JJ Cook","year":"2010","unstructured":"Cook, J. J., Wildsmith, K. R., Gilberto, D. B., Holahan, M. A., Kinney, G. G., Mathers, P. D., et al. (2010). Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. Journal of Neuroscience, 30(19), 6743\u20136750.","journal-title":"Journal of Neuroscience"},{"issue":"2","key":"8208_CR16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1152\/physrev.00023.2009","volume":"90","author":"B Strooper De","year":"2010","unstructured":"De Strooper, B. (2010). Proteases and proteolysis in Alzheimer disease: A multifactorial view on the disease process. Physiological Reviews, 90(2), 465\u2013494.","journal-title":"Physiological Reviews"},{"issue":"Pt 5","key":"8208_CR17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1042\/BST20051101","volume":"33","author":"EA Eckman","year":"2005","unstructured":"Eckman, E. A., & Eckman, C. B. (2005). Abeta-degrading enzymes: Modulators of Alzheimer\u2019s disease pathogenesis and targets for therapeutic intervention. Biochemical Society Transactions, 33(Pt 5), 1101\u20131105.","journal-title":"Biochemical Society Transactions"},{"issue":"3","key":"8208_CR18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1515\/CCLM.2011.077","volume":"49","author":"M Eller","year":"2011","unstructured":"Eller, M., & Williams, D. R. (2011). Alpha-synuclein in Parkinson disease and other neurodegenerative disorders. Clinical Chemistry and Laboratory Medicine, 49(3), 403\u2013408.","journal-title":"Clinical Chemistry and Laboratory Medicine"},{"key":"8208_CR19","doi-asserted-by":"crossref","unstructured":"Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., et al. (2007). Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Movement Disorders, 22(12), 1689\u20131707; quiz 1837.","DOI":"10.1002\/mds.21507"},{"issue":"7","key":"8208_CR20","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/archneur.55.7.937","volume":"55","author":"D Galasko","year":"1998","unstructured":"Galasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., et al. (1998). High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Archives of Neurology, 55(7), 937\u2013945.","journal-title":"Archives of Neurology"},{"issue":"1","key":"8208_CR21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archneur.56.1.33","volume":"56","author":"DJ Gelb","year":"1999","unstructured":"Gelb, D. J., Oliver, E., & Gilman, S. (1999). Diagnostic criteria for Parkinson disease. Archives of Neurology, 56(1), 33\u201339.","journal-title":"Archives of Neurology"},{"issue":"1","key":"8208_CR22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0022-510X(98)00304-9","volume":"163","author":"S Gilman","year":"1999","unstructured":"Gilman, S., Low, P. A., Quinn, N., Albanese, A., Ben-Shlomo, Y., Fowler, C. J., et al. (1999). Consensus statement on the diagnosis of multiple system atrophy. Journal of the Neurological Sciences, 163(1), 94\u201398.","journal-title":"Journal of the Neurological Sciences"},{"key":"8208_CR23","doi-asserted-by":"crossref","unstructured":"Hall, S., \u00d6hrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostr\u00f6m, F., et al. (2012). A panel of five CSF biomarker can be used with high accuracy in the differential diagnosis of patients with dementia and\/or Parkinsonism. Archives of Neurology.","DOI":"10.1001\/archneurol.2012.1654"},{"issue":"7","key":"8208_CR24","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrd3115","volume":"9","author":"H Hampel","year":"2010","unstructured":"Hampel, H., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., et al. (2010). Biomarkers for Alzheimer\u2019s disease: Academic, industry and regulatory perspectives. Nature Reviews Drug Discovery, 9(7), 560\u2013574.","journal-title":"Nature Reviews Drug Discovery"},{"issue":"5","key":"8208_CR25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000100926","volume":"23","author":"O Hansson","year":"2007","unstructured":"Hansson, O., Zetterberg, H., Buchhave, P., Andreasson, U., Londos, E., Minthon, L., et al. (2007). Prediction of Alzheimer\u2019s disease using the CSF Abeta42\/Abeta40 ratio in patients with mild cognitive impairment. Dementia and Geriatric Cognitive Disorders, 23(5), 316\u2013320.","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"5","key":"8208_CR26","first-page":"277","volume":"27","author":"D Hendriks","year":"1989","unstructured":"Hendriks, D., Scharpe, S., van Sande, M., & Lommaert, M. P. (1989). Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. Journal of Clinical Chemistry and Clinical Biochemistry, 27(5), 277\u2013285.","journal-title":"Journal of Clinical Chemistry and Clinical Biochemistry"},{"key":"8208_CR27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-3-7091-6846-2_6","volume":"Suppl 51","author":"KA Jellinger","year":"1997","unstructured":"Jellinger, K. A. (1997). Morphological substrates of dementia in Parkinsonism. A critical update. Journal of Neural Transmission, Suppl 51, 57\u201382.","journal-title":"Journal of Neural Transmission"},{"issue":"5","key":"8208_CR28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrneurol.2011.43","volume":"7","author":"N Kouri","year":"2011","unstructured":"Kouri, N., Whitwell, J. L., Josephs, K. A., Rademakers, R., & Dickson, D. W. (2011). Corticobasal degeneration: A pathologically distinct 4R tauopathy. Nature Review Neurology, 7(5), 263\u2013272.","journal-title":"Nature Review Neurology"},{"issue":"17","key":"8208_CR29","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1038\/emboj.2010.167","volume":"29","author":"PH Kuhn","year":"2010","unstructured":"Kuhn, P. H., Wang, H., Dislich, B., Colombo, A., Zeitschel, U., Ellwart, J. W., et al. (2010). ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO Journal, 29(17), 3020\u20133032.","journal-title":"EMBO Journal"},{"issue":"1","key":"8208_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., et al. (1996a). Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop. Neurology, 47(1), 1\u20139.","journal-title":"Neurology"},{"issue":"1","key":"8208_CR31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00005072-199601000-00010","volume":"55","author":"I Litvan","year":"1996","unstructured":"Litvan, I., Hauw, J. J., Bartko, J. J., Lantos, P. L., Daniel, S. E., Horoupian, D. S., et al. (1996b). Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. Journal of Neuropathology and Experimental Neurology, 55(1), 97\u2013105.","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"issue":"5","key":"8208_CR32","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1634\/stemcells.2007-0725","volume":"26","author":"L Marquez-Curtis","year":"2008","unstructured":"Marquez-Curtis, L., Jalili, A., Deiteren, K., Shirvaikar, N., Lambeir, A. M., & Janowska-Wieczorek, A. (2008). Carboxypeptidase M expressed by human bone marrow cells cleaves the C-terminal lysine of stromal cell-derived factor-1alpha: Another player in hematopoietic stem\/progenitor cell mobilization? Stem Cells, 26(5), 1211\u20131220.","journal-title":"Stem Cells"},{"issue":"12","key":"8208_CR33","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proceedings of the National Academy of Sciences of the United States of America, 82(12), 4245\u20134249.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"8208_CR34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1460-9568.2000.00908.x","volume":"12","author":"A Matsumoto","year":"2000","unstructured":"Matsumoto, A., Itoh, K., & Matsumoto, R. (2000). A novel carboxypeptidase B that processes native beta-amyloid precursor protein is present in human hippocampus. European Journal of Neuroscience, 12(1), 227\u2013238.","journal-title":"European Journal of Neuroscience"},{"issue":"9","key":"8208_CR35","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1046\/j.0953-816x.2001.01540.x","volume":"13","author":"A Matsumoto","year":"2001","unstructured":"Matsumoto, A., Itoh, K., Seki, T., Motozaki, K., & Matsuyama, S. (2001). Human brain carboxypeptidase B, which cleaves beta-amyloid peptides in vitro, is expressed in the endoplasmic reticulum of neurons. European Journal of Neuroscience, 13(9), 1653\u20131657.","journal-title":"European Journal of Neuroscience"},{"issue":"1","key":"8208_CR36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/scnp.2003.50006","volume":"8","author":"IG McKeith","year":"2003","unstructured":"McKeith, I. G., Burn, D. J., Ballard, C. G., Collerton, D., Jaros, E., Morris, C. M., et al. (2003). Dementia with Lewy bodies. Seminars in Clinical Neuropsychiatry, 8(1), 46\u201357.","journal-title":"Seminars in Clinical Neuropsychiatry"},{"issue":"12","key":"8208_CR37","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"IG McKeith","year":"2005","unstructured":"McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O\u2019Brien, J. T., Feldman, H., et al. (2005). Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology, 65(12), 1863\u20131872.","journal-title":"Neurology"},{"issue":"7","key":"8208_CR38","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer\u2019s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology, 34(7), 939\u2013944.","journal-title":"Neurology"},{"issue":"1","key":"8208_CR39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/archneur.57.1.100","volume":"57","author":"PD Mehta","year":"2000","unstructured":"Mehta, P. D., Pirttila, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000). Plasma and cerebrospinal fluid levels of amyloid beta proteins 1\u201340 and 1\u201342 in Alzheimer disease. Archives of Neurology, 57(1), 100\u2013105.","journal-title":"Archives of Neurology"},{"issue":"2","key":"8208_CR40","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","volume":"213","author":"B Mollenhauer","year":"2008","unstructured":"Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., et al. (2008). Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Experimental Neurology, 213(2), 315\u2013325.","journal-title":"Experimental Neurology"},{"issue":"1","key":"8208_CR41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0014-4886(03)00027-X","volume":"183","author":"A Olsson","year":"2003","unstructured":"Olsson, A., Hoglund, K., Sjogren, M., Andreasen, N., Minthon, L., Lannfelt, L., et al. (2003). Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Experimental Neurology, 183(1), 74\u201380.","journal-title":"Experimental Neurology"},{"issue":"1","key":"8208_CR42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/0003-9861(75)90104-6","volume":"170","author":"G Oshima","year":"1975","unstructured":"Oshima, G., Kato, J., & Erdos, E. G. (1975). Plasma carboxypeptidase N, subunits and characteristics. Archives of Biochemistry and Biophysics, 170(1), 132\u2013138.","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"8208_CR43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1750-1326-5-2","volume":"5","author":"E Portelius","year":"2010","unstructured":"Portelius, E., Andreasson, U., Ringman, J. M., Buerger, K., Daborg, J., Buchhave, P., et al. (2010a). Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer\u2019s disease. Molecular Neurodegeneration, 5, 2.","journal-title":"Molecular Neurodegeneration"},{"issue":"2","key":"8208_CR44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/alzrt30","volume":"2","author":"E Portelius","year":"2010","unstructured":"Portelius, E., Dean, R. A., Gustavsson, M. K., Andreasson, U., Zetterberg, H., Siemers, E., et al. (2010b). A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimer\u2019s Research & Therapy, 2(2), 7.","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"6","key":"8208_CR45","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.neurobiolaging.2009.06.002","volume":"32","author":"E Portelius","year":"2011","unstructured":"Portelius, E., Price, E., Brinkmalm, G., Stiteler, M., Olsson, M., Persson, R., et al. (2011). A novel pathway for amyloid precursor protein processing. Neurobiology of Aging, 32(6), 1090\u20131098.","journal-title":"Neurobiology of Aging"},{"issue":"11","key":"8208_CR46","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1021\/pr0703627","volume":"6","author":"E Portelius","year":"2007","unstructured":"Portelius, E., Tran, A. J., Andreasson, U., Persson, R., Brinkmalm, G., Zetterberg, H., et al. (2007). Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. Journal of Proteome Research, 6(11), 4433\u20134439.","journal-title":"Journal of Proteome Research"},{"issue":"3","key":"8208_CR47","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3233\/JAD-2010-100573","volume":"21","author":"E Portelius","year":"2010","unstructured":"Portelius, E., Van Broeck, B., Andreasson, U., Gustavsson, M. K., Mercken, M., Zetterberg, H., et al. (2010c). Acute effect on the Abeta isoform pattern in CSF in response to gamma-secretase modulator and inhibitor treatment in dogs. Journal of Alzheimer\u2019s disease, 21(3), 1005\u20131012.","journal-title":"Journal of Alzheimer\u2019s disease"},{"issue":"3","key":"8208_CR48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neulet.2006.09.044","volume":"409","author":"E Portelius","year":"2006","unstructured":"Portelius, E., Zetterberg, H., Andreasson, U., Brinkmalm, G., Andreasen, N., Wallin, A., et al. (2006). An Alzheimer\u2019s disease-specific beta-amyloid fragment signature in cerebrospinal fluid. Neuroscience Letters, 409(3), 215\u2013219.","journal-title":"Neuroscience Letters"},{"key":"8208_CR49","doi-asserted-by":"crossref","unstructured":"Portelius, E., Zetterberg, H., Dean, R. A., Marcil, A., Bourgeois, P., Nutu, M., et al. (2012). Amyloid-beta1-15\/16 as a marker for gamma-secretase inhibition in Alzheimer\u2019s Disease. Journal of Alzheimers Disease.","DOI":"10.3233\/JAD-2012-120508"},{"issue":"5\u20136","key":"8208_CR50","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000264639","volume":"6","author":"E Portelius","year":"2009","unstructured":"Portelius, E., Zhang, B., Gustavsson, M. K., Brinkmalm, G., Westman-Brinkmalm, A., Zetterberg, H., et al. (2009). Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer\u2019s disease. Neurodegeneration Disease, 6(5\u20136), 258\u2013262.","journal-title":"Neurodegeneration Disease"},{"issue":"48","key":"8208_CR51","doi-asserted-by":"crossref","first-page":"14328","DOI":"10.1021\/bi035038d","volume":"42","author":"SK Rangan","year":"2003","unstructured":"Rangan, S. K., Liu, R., Brune, D., Planque, S., Paul, S., & Sierks, M. R. (2003). Degradation of beta-amyloid by proteolytic antibody light chains. Biochemistry, 42(48), 14328\u201314334.","journal-title":"Biochemistry"},{"issue":"1","key":"8208_CR52","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archneur.1968.00470310034003","volume":"18","author":"JJ Rebeiz","year":"1968","unstructured":"Rebeiz, J. J., Kolodny, E. H., & Richardson, E. P., Jr. (1968). Corticodentatonigral degeneration with neuronal achromasia. Archives of Neurology, 18(1), 20\u201333.","journal-title":"Archives of Neurology"},{"key":"8208_CR53","unstructured":"Santacruz, K., Pahwa, R., Lyons, K., Troster, A., Handler, M., Koller, WC., et al (1999). Lewy body, neurofibrillary tangle and senile plaque pathology in Parkinson\u2019s disease patients with and without dementia. Neurology, 52 (Suppl. 2)(A476)."},{"issue":"1","key":"8208_CR54","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ana.20508","volume":"58","author":"NS Schoonenboom","year":"2005","unstructured":"Schoonenboom, N. S., Mulder, C., Van Kamp, G. J., Mehta, S. P., Scheltens, P., Blankenstein, M. A., et al. (2005). Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: More of the same? Annuals of Neurology, 58(1), 139\u2013142.","journal-title":"Annuals of Neurology"},{"issue":"5","key":"8208_CR55","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1096\/fj.07-9357com","volume":"22","author":"RA Sharples","year":"2008","unstructured":"Sharples, R. A., Vella, L. J., Nisbet, R. M., Naylor, R., Perez, K., Barnham, K. J., et al. (2008). Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB J, 22(5), 1469\u20131478.","journal-title":"FASEB J"},{"key":"8208_CR56","unstructured":"Skidgel, R. A. (1996). Structure and function of mammalian zinc carboxypeptidase. In N. M. Hooper (Ed.), Zinc metalloprotease in health and disease. London: Taylor & Francis, pp. 241\u2013283."},{"key":"8208_CR57","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/archneur.1964.00460160003001","volume":"10","author":"JC Steele","year":"1964","unstructured":"Steele, J. C., Richardson, J. C., & Olszewski, J. (1964). Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, Nuchal Dystonia and Dementia. Archives of Neurology, 10, 333\u2013359.","journal-title":"Archives of Neurology"},{"issue":"3","key":"8208_CR58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/alzrt44","volume":"2","author":"E Stomrud","year":"2010","unstructured":"Stomrud, E., Bjorkqvist, M., Janciauskiene, S., Minthon, L., & Hansson, O. (2010). Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer\u2019s disease. Alzheimers Research Therapy, 2(3), 20.","journal-title":"Alzheimers Research Therapy"},{"issue":"9","key":"8208_CR59","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/mds.22895","volume":"25","author":"SD Sussmuth","year":"2010","unstructured":"Sussmuth, S. D., Uttner, I., Landwehrmeyer, B., Pinkhardt, E. H., Brettschneider, J., Petzold, A., et al. (2010). Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes. Movement Disorders, 25(9), 1284\u20131288.","journal-title":"Movement Disorders"},{"issue":"2","key":"8208_CR60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1087057107312778","volume":"13","author":"PG Szekeres","year":"2008","unstructured":"Szekeres, P. G., Leong, K., Day, T. A., Kingston, A. E., & Karran, E. H. (2008). Development of homogeneous 384-well high-throughput screening assays for Abeta1-40 and Abeta1-42 using AlphaScreen technology. Journal of Biomolecular Screening, 13(2), 101\u2013111.","journal-title":"Journal of Biomolecular Screening"},{"issue":"18","key":"8208_CR61","doi-asserted-by":"crossref","first-page":"12619","DOI":"10.1074\/jbc.274.18.12619","volume":"274","author":"LO Tjernberg","year":"1999","unstructured":"Tjernberg, L. O., Callaway, D. J., Tjernberg, A., Hahne, S., Lilliehook, C., Terenius, L., et al. (1999). A molecular model of Alzheimer amyloid beta-peptide fibril formation. Journal of Biological Chemistry, 274(18), 12619\u201312625.","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"8208_CR62","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bbrc.2006.08.024","volume":"349","author":"T Tokuda","year":"2006","unstructured":"Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., et al. (2006). Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson\u2019s disease. Biochemical and Biophysical Research Communications, 349(1), 162\u2013166.","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"4","key":"8208_CR63","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/13506120009146438","volume":"7","author":"H Vanderstichele","year":"2000","unstructured":"Vanderstichele, H., Van Kerschaver, E., Hesse, C., Davidsson, P., Buyse, M. A., Andreasen, N., et al. (2000). Standardization of measurement of beta-amyloid(1\u201342) in cerebrospinal fluid and plasma. Amyloid, 7(4), 245\u2013258.","journal-title":"Amyloid"},{"issue":"5","key":"8208_CR64","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1111\/j.1471-4159.1993.tb09841.x","volume":"61","author":"C Vigo-Pelfrey","year":"1993","unstructured":"Vigo-Pelfrey, C., Lee, D., Keim, P., Lieberburg, I., & Schenk, D. B. (1993). Characterization of beta-amyloid peptide from human cerebrospinal fluid. Journal of Neurochemistry, 61(5), 1965\u20131968.","journal-title":"Journal of Neurochemistry"},{"issue":"22","key":"8208_CR65","doi-asserted-by":"crossref","first-page":"15937","DOI":"10.1016\/S0021-9258(17)40771-X","volume":"269","author":"W Wang","year":"1994","unstructured":"Wang, W., Hendriks, D. F., & Scharpe, S. S. (1994). Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. Journal of Biological Chemistry, 269(22), 15937\u201315944.","journal-title":"Journal of Biological Chemistry"},{"issue":"8","key":"8208_CR66","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1021\/bi015794o","volume":"41","author":"A Weidemann","year":"2002","unstructured":"Weidemann, A., Eggert, S., Reinhard, F. B., Vogel, M., Paliga, K., Baier, G., et al. (2002). A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with notch processing. Biochemistry, 41(8), 2825\u20132835.","journal-title":"Biochemistry"},{"issue":"3","key":"8208_CR67","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1046\/j.1471-4159.2002.00818.x","volume":"81","author":"J Wiltfang","year":"2002","unstructured":"Wiltfang, J., Esselmann, H., Bibl, M., Smirnov, A., Otto, M., Paul, S., et al. (2002). Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1\u201337\/38\/39 in addition to 1\u201340\/42 in Alzheimer\u2019s disease and in patients with chronic neuroinflammation. Journal of Neurochemistry, 81(3), 481\u2013496.","journal-title":"Journal of Neurochemistry"},{"issue":"24","key":"8208_CR68","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1073\/pnas.82.24.8729","volume":"82","author":"CW Wong","year":"1985","unstructured":"Wong, C. W., Quaranta, V., & Glenner, G. G. (1985). Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. Proceedings of the National Academy of Sciences of the United States of America, 82(24), 8729\u20138732.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"47","key":"8208_CR69","doi-asserted-by":"crossref","first-page":"43756","DOI":"10.1074\/jbc.C100410200","volume":"276","author":"C Yu","year":"2001","unstructured":"Yu, C., Kim, S. H., Ikeuchi, T., Xu, H., Gasparini, L., Wang, R., et al. (2001). Characterization of a presenilin-mediated amyloid precursor protein carboxyl-terminal fragment gamma. Evidence for distinct mechanisms involved in gamma-secretase processing of the APP and Notch1 transmembrane domains. Journal of Biological Chemistry, 276(47), 43756\u201343760.","journal-title":"Journal of Biological Chemistry"},{"issue":"4","key":"8208_CR70","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1309\/W01Y0B808EMEH12L","volume":"129","author":"J Zhang","year":"2008","unstructured":"Zhang, J., Sokal, I., Peskind, E. R., Quinn, J. F., Jankovic, J., Kenney, C., et al. (2008). CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. American Journal of Clinical Pathology, 129(4), 526\u2013529.","journal-title":"American Journal of Clinical Pathology"},{"issue":"49","key":"8208_CR71","doi-asserted-by":"crossref","first-page":"50647","DOI":"10.1074\/jbc.C400473200","volume":"279","author":"G Zhao","year":"2004","unstructured":"Zhao, G., Mao, G., Tan, J., Dong, Y., Cui, M. Z., Kim, S. H., et al. (2004). Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein. Journal of Biological Chemistry, 279(49), 50647\u201350650.","journal-title":"Journal of Biological Chemistry"}],"container-title":["NeuroMolecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12017-012-8208-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12017-012-8208-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12017-012-8208-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T11:40:21Z","timestamp":1643802021000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12017-012-8208-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,7]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["8208"],"URL":"https:\/\/doi.org\/10.1007\/s12017-012-8208-8","relation":{},"ISSN":["1535-1084","1559-1174"],"issn-type":[{"value":"1535-1084","type":"print"},{"value":"1559-1174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,7]]}}}